Galectin Therapeutics (GALT) Shares Outstanding (Diluted Average) (2020 - 2026)

Galectin Therapeutics has reported Shares Outstanding (Diluted Average) for 7 years, with the latest figure at $65.8 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 4.08% year-over-year to $65.8 million; the trailing twelve-month figure through Mar 2026 stood at $65.8 million (up 4.08% YoY), and the FY2025 full-year result was $63.9 million, up 2.56% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $65.8 million, up from $63.9 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $65.8 million in Q1 2026, with the low at $59.4 million in Q1 2022.
• Average Shares Outstanding (Diluted Average) over 5 years is $61.5 million, with a median of $62.0 million recorded in 2024.
• Year-over-year, Shares Outstanding (Diluted Average) gained 0.21% in 2023 and rose 4.23% in 2024.
• Tracing GALT's Shares Outstanding (Diluted Average) over 5 years: stood at $59.4 million in 2022, then gained by 1.29% to $60.2 million in 2023, then advanced by 3.57% to $62.3 million in 2024, then increased by 2.56% to $63.9 million in 2025, then gained by 2.94% to $65.8 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $65.8 million (Q1 2026), $63.9 million (Q4 2025), and $63.6 million (Q3 2025), per Business Quant data.

Peer Comparison